SE501389C2 - Farmaceutiskt preparat och förfarande för dess framställning - Google Patents
Farmaceutiskt preparat och förfarande för dess framställningInfo
- Publication number
- SE501389C2 SE501389C2 SE9201299A SE9201299A SE501389C2 SE 501389 C2 SE501389 C2 SE 501389C2 SE 9201299 A SE9201299 A SE 9201299A SE 9201299 A SE9201299 A SE 9201299A SE 501389 C2 SE501389 C2 SE 501389C2
- Authority
- SE
- Sweden
- Prior art keywords
- preparation
- film
- tablet
- dissolves
- bisphosphonic acid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 4
- 238000000034 method Methods 0.000 title claims description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims description 21
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 5
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 4
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229960002286 clodronic acid Drugs 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000002662 enteric coated tablet Substances 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 101150008563 spir gene Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (22)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9201299A SE501389C2 (sv) | 1992-04-24 | 1992-04-24 | Farmaceutiskt preparat och förfarande för dess framställning |
| TW082102782A TW273515B (da) | 1992-04-24 | 1993-04-13 | |
| IL105403A IL105403A (en) | 1992-04-24 | 1993-04-15 | Pharmaceutical preparation containing dichloromethylene bisphosphonic acid and process for its manufacture |
| EP93908973A EP0637236B1 (en) | 1992-04-24 | 1993-04-21 | Pharmaceutical preparation and process for its manufacture |
| HU9403067A HU219342B (en) | 1992-04-24 | 1993-04-21 | Oral pharmaceutical preparation comprising clodronate as active ingredient and process for its manufacture |
| JP51895893A JP3536106B2 (ja) | 1992-04-24 | 1993-04-21 | 製剤及びその製造方法 |
| AU39550/93A AU671830B2 (en) | 1992-04-24 | 1993-04-21 | A Pharmaceutical Preparation of Dichloromethylene Bisphosphonic Acid with Enteric Coating for Oral Use |
| AT93908973T ATE143802T1 (de) | 1992-04-24 | 1993-04-21 | Pharmazeutische zubereitung und verfahren für ihre herstellung |
| US08/318,650 US5525354A (en) | 1992-04-24 | 1993-04-21 | Pharmaceutical preparation and process for its manufacture |
| DE0637236T DE637236T1 (de) | 1992-04-24 | 1993-04-21 | Pharmazeutische zubereitung und verfahren für ihre herstellung. |
| RU94045950A RU2116074C1 (ru) | 1992-04-24 | 1993-04-21 | Фармацевтический препарат и способ его приготовления |
| CZ942614A CZ282871B6 (cs) | 1992-04-24 | 1993-04-21 | Farmaceutický přípravek pro orální použití a způsob jeho výroby |
| ES93908973T ES2094539T3 (es) | 1992-04-24 | 1993-04-21 | Preparacion farmaceutica y procedimiento para su preparacion. |
| DK93908973.6T DK0637236T3 (da) | 1992-04-24 | 1993-04-21 | Farmaceutisk præparat og fremgangsmåde til dets fremstilling |
| PCT/FI1993/000166 WO1993021907A1 (en) | 1992-04-24 | 1993-04-21 | Pharmaceutical preparation and process for its manufacture |
| CA002134196A CA2134196C (en) | 1992-04-24 | 1993-04-21 | Pharmaceutical preparation and process for its manufacture |
| DE69305335T DE69305335T2 (de) | 1992-04-24 | 1993-04-21 | Pharmazeutische zubereitung und verfahren für ihre herstellung |
| FI944961A FI110667B (fi) | 1992-04-24 | 1994-10-21 | Menetelmä farmaseuttisen valmisteen valmistamiseksi |
| NO944001A NO306654B1 (no) | 1992-04-24 | 1994-10-21 | Farmasöytisk preparat inneholdende diklormetylenbisfosfonsyre eller salt derav for oral tilförsel |
| EE9400134A EE03107B1 (et) | 1992-04-24 | 1994-11-15 | Ravimpreparaat ja meetod selle valmistamiseks |
| GR970400013T GR3022249T3 (en) | 1992-04-24 | 1997-01-09 | Pharmaceutical preparation and process for its manufacture. |
| HK13097A HK13097A (en) | 1992-04-24 | 1997-02-05 | Pharmaceutical preparation and process for its manufacture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9201299A SE501389C2 (sv) | 1992-04-24 | 1992-04-24 | Farmaceutiskt preparat och förfarande för dess framställning |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9201299D0 SE9201299D0 (sv) | 1992-04-24 |
| SE9201299L SE9201299L (sv) | 1993-10-25 |
| SE501389C2 true SE501389C2 (sv) | 1995-01-30 |
Family
ID=20386054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9201299A SE501389C2 (sv) | 1992-04-24 | 1992-04-24 | Farmaceutiskt preparat och förfarande för dess framställning |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5525354A (da) |
| EP (1) | EP0637236B1 (da) |
| JP (1) | JP3536106B2 (da) |
| AT (1) | ATE143802T1 (da) |
| AU (1) | AU671830B2 (da) |
| CA (1) | CA2134196C (da) |
| CZ (1) | CZ282871B6 (da) |
| DE (2) | DE69305335T2 (da) |
| DK (1) | DK0637236T3 (da) |
| EE (1) | EE03107B1 (da) |
| ES (1) | ES2094539T3 (da) |
| FI (1) | FI110667B (da) |
| GR (1) | GR3022249T3 (da) |
| HK (1) | HK13097A (da) |
| HU (1) | HU219342B (da) |
| IL (1) | IL105403A (da) |
| NO (1) | NO306654B1 (da) |
| RU (1) | RU2116074C1 (da) |
| SE (1) | SE501389C2 (da) |
| TW (1) | TW273515B (da) |
| WO (1) | WO1993021907A1 (da) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406714B1 (en) | 1992-12-02 | 2002-06-18 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids |
| BR9307859A (pt) † | 1993-05-15 | 1996-01-09 | Boehringer Mannheim Gmbh | Comprimido com biodisponibilidade aperfeiçoada que contérn ácido |
| US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
| FI94926C (fi) * | 1993-11-12 | 1995-11-27 | Leiras Oy | Menetelmä klodronaattivalmisteen valmistamiseksi |
| US20010007863A1 (en) | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
| TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
| FI98343C (fi) * | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
| DE19719680A1 (de) | 1997-05-09 | 1998-11-19 | Boehringer Mannheim Gmbh | Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz |
| JPH11137208A (ja) * | 1997-11-14 | 1999-05-25 | Nikken Chem Co Ltd | 口腔内速溶性固形物及びその製造方法 |
| EP0998933A1 (de) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
| EP0998932A1 (de) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| CA2363123C (en) * | 1999-02-22 | 2011-09-06 | Kenneth Iain Cumming | Solid oral dosage form containing an enhancer |
| SE9901272D0 (sv) * | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| US6410520B2 (en) | 2000-02-01 | 2002-06-25 | The Procter & Gamble Company | Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate |
| US6562974B2 (en) | 2000-02-01 | 2003-05-13 | The Procter & Gamble Company | Process for making geminal bisphosphonates |
| NZ527157A (en) * | 2001-03-01 | 2005-04-29 | Emisphere Tech Inc | Compositions for delivering bisphosphonates |
| EP1390383B1 (en) | 2001-05-11 | 2012-02-29 | Isis Pharmaceuticals, Inc. | Antisense permeation enhancers |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
| US8309118B2 (en) * | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| WO2007117706A2 (en) | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| CN102046192B (zh) | 2008-05-07 | 2014-11-19 | 默里昂研究Ⅲ有限公司 | GnRH相关化合物的组合物及制备方法 |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| WO2012094598A2 (en) | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
| DE3767998D1 (de) * | 1986-12-20 | 1991-03-14 | Boehringer Mannheim Gmbh | Clodronat-haltige arzneimittel und verfahren zur herstellung derselben. |
| EP0313845A1 (en) * | 1987-09-29 | 1989-05-03 | Warner-Lambert Company | Stabilization of enteric coated dosage form |
| FR2629716B1 (fr) * | 1988-04-07 | 1991-07-19 | Sanofi Sa | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique |
-
1992
- 1992-04-24 SE SE9201299A patent/SE501389C2/sv not_active IP Right Cessation
-
1993
- 1993-04-13 TW TW082102782A patent/TW273515B/zh active
- 1993-04-15 IL IL105403A patent/IL105403A/en not_active IP Right Cessation
- 1993-04-21 DE DE69305335T patent/DE69305335T2/de not_active Expired - Fee Related
- 1993-04-21 US US08/318,650 patent/US5525354A/en not_active Expired - Lifetime
- 1993-04-21 AU AU39550/93A patent/AU671830B2/en not_active Ceased
- 1993-04-21 RU RU94045950A patent/RU2116074C1/ru not_active IP Right Cessation
- 1993-04-21 CZ CZ942614A patent/CZ282871B6/cs not_active IP Right Cessation
- 1993-04-21 AT AT93908973T patent/ATE143802T1/de not_active IP Right Cessation
- 1993-04-21 JP JP51895893A patent/JP3536106B2/ja not_active Expired - Fee Related
- 1993-04-21 ES ES93908973T patent/ES2094539T3/es not_active Expired - Lifetime
- 1993-04-21 CA CA002134196A patent/CA2134196C/en not_active Expired - Fee Related
- 1993-04-21 EP EP93908973A patent/EP0637236B1/en not_active Expired - Lifetime
- 1993-04-21 HU HU9403067A patent/HU219342B/hu not_active IP Right Cessation
- 1993-04-21 DK DK93908973.6T patent/DK0637236T3/da active
- 1993-04-21 DE DE0637236T patent/DE637236T1/de active Pending
- 1993-04-21 WO PCT/FI1993/000166 patent/WO1993021907A1/en not_active Ceased
-
1994
- 1994-10-21 FI FI944961A patent/FI110667B/fi active
- 1994-10-21 NO NO944001A patent/NO306654B1/no unknown
- 1994-11-15 EE EE9400134A patent/EE03107B1/xx not_active IP Right Cessation
-
1997
- 1997-01-09 GR GR970400013T patent/GR3022249T3/el unknown
- 1997-02-05 HK HK13097A patent/HK13097A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5525354A (en) | Pharmaceutical preparation and process for its manufacture | |
| US6537573B2 (en) | Combination dosage form comprising cetirizine and pseudoephedrine | |
| US6156343A (en) | Controlled release preparation | |
| AU2009311877C1 (en) | Pharmaceutical composition for release control of methylphenidate | |
| CZ296964B6 (cs) | Farmaceutické formulace tramadolu v násobných jednotkách a zpusob jejich výroby | |
| WO1997048386A1 (en) | Enteric coated diltiazem once-a-day formulation | |
| Cui et al. | In vitro and in vivo evaluation of ofloxacin sustained release pellets | |
| ES2756711T3 (es) | Formulaciones estabilizadas de compuestos del SNC | |
| JPH02164821A (ja) | 新規な投与形態 | |
| US20140127294A1 (en) | Oral solid formulation of compound anti-tubercular drug and preparation method thereof | |
| ES2860694T3 (es) | Composición farmacéutica de liberación sostenida que contiene rivastigmina | |
| WO2023090720A1 (ko) | 산 민감성 성분을 포함하는 삼투성 제제 조성물 | |
| JP2001131059A (ja) | 多細孔性食物防護 | |
| WO2018165781A1 (zh) | 一种含有愈创木酚甘油醚的剂型组成及其应用 | |
| JPH08208476A (ja) | ニフェジピン含有持続性製剤 | |
| GB2258810A (en) | Pharmaceutical combination formulation of diltiazem and hydrochlorothiazide | |
| CN117679382A (zh) | 吗替麦考酚酯胃黏附渗透泵控释片及其制备方法 | |
| KR20230148924A (ko) | 콜린 알포세레이트를 포함하는 서방성코팅 연질캡슐 제제 및 이의 제조 방법 | |
| LV10382B (en) | New medicinal preparation | |
| KR20080071286A (ko) | 암로디핀 함유 입자 및 그것을 포함하는 구강 내 붕괴정 | |
| HRP920630A2 (en) | New pharmaceutical preparations having extended delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |